Literature DB >> 16745524

Conditions of hypertrophy of seminal vesicles in rats: The effect of derivatives of oestrone (menformon).

K David1, J Freud, S E De Jongh.   

Abstract

Entities:  

Year:  1934        PMID： 16745524      PMCID： PMC1253345          DOI： 10.1042/bj0281360

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


× No keyword cloud information.
  2 in total

1.  The chemistry of oestrin: The mechanism of the conversion of trihydroxyoestrin into ketohydroxyoestrin.

Authors:  G F Marrian; G A Haslewood
Journal:  Biochem J       Date:  1932       Impact factor: 3.857

2.  Conditions of hypertrophy of the seminal vesicles in rats.

Authors:  J Freud
Journal:  Biochem J       Date:  1933       Impact factor: 3.857
  2 in total
  7 in total

1.  The assay and the effect of testosterone on rats compared with those of other sexual hormones.

Authors:  V Korenchevsky; M Dennison; I Brovsin
Journal:  Biochem J       Date:  1936-03       Impact factor: 3.857

2.  Effect of androsterone and of male hormone concentrates on the accessory reproductive organs of castrated rats, mice and guinea-pigs.

Authors:  R K Callow; R Deanesly
Journal:  Biochem J       Date:  1935-06       Impact factor: 3.857

3.  Benign nodular hyperplasia of the prostate; a review.

Authors:  L M FRANKS
Journal:  Ann R Coll Surg Engl       Date:  1953-02       Impact factor: 1.891

4.  The Sex Hormones and Their Value as Therapeutic Agents.

Authors:  M C Watson
Journal:  Can Med Assoc J       Date:  1936-03       Impact factor: 8.262

5.  OBSERVATIONS ON THE TREATMENT OF DYSMENORRHOEA WITH THE PLACENTAL EXTRACT "EMMENIN".

Authors:  M C Watson
Journal:  Can Med Assoc J       Date:  1935-06       Impact factor: 8.262

6.  The Endocrine Control of the Prostate: (Section of Urology).

Authors:  S Zuckerman
Journal:  Proc R Soc Med       Date:  1936-10

7.  The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses. Phase 1: use of a potent agonist and a potent antagonist to test the standardized protocol.

Authors:  William Owens; Errol Zeiger; Michael Walker; John Ashby; Lesley Onyon; L Earl Gray
Journal:  Environ Health Perspect       Date:  2006-08       Impact factor: 9.031
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.